Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Medicine

Safety, efficacy, and biomarker analysis of HTMC0435 plus temozolomide in relapsed extensive-stage small-cell lung cancer: A phase Ib/II trial

  • Sizhe Yu
  • Lei Gong
  • Jun Qian
  • Yanqiu Zhao
  • Kaiyan Chen
  • Hui Li
  • Yanjun Xu
  • Guang Han
  • Xue Meng
  • Jing Qin
  • Hongyang Lu
  • Na Han
4 more authors
  • Cuiping Gu
  • Yan Cheng
  • Zhiyu Huang
  • Yun Fan
Open at sourceDOICite

Related

  1. Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China
    Yan Jin, Benfu Zhong, Jiarun Fu +14
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textOncologyCrossrefPMC
  2. Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms
    Beyza Ozturk, Asuman Celebi, Deniz Kilic +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML
    P. Bhardwaj, A. Baassiri, R. K. Sundaram +9
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. TMBIM4 acts as a novel prognostic biomarker for glioblastoma and is associated with temozolomide chemoresistance.
    Jianeng Pu, Tianhua Li, Shuai Zhou +1
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Improved efficacy of orelabrutinib plus rituximab, temozolomide and high-dose methotrexate versus rituximab, high-dose methotrexate plus temozolomide in untreated primary CNS lymphoma: A matched analysis
    Peng Zhang, Man Nie, Hang Yang +8
    Neuro-Oncology AdvancesPeer-reviewedCC BY-NC 4.0Full textNeurologyPMC

Cite

BibTeXRIS
BibTeX
@article{yu2026safety,
  title = {{Safety, efficacy, and biomarker analysis of HTMC0435 plus temozolomide in relapsed extensive-stage small-cell lung cancer: A phase Ib/II trial}},
  author = {Sizhe Yu and Lei Gong and Jun Qian and Yanqiu Zhao and Kaiyan Chen and Hui Li and Yanjun Xu and Guang Han and Xue Meng and Jing Qin and Hongyang Lu and Na Han and Cuiping Gu and Yan Cheng and Zhiyu Huang and Yun Fan},
  journal = {BMC Medicine},
  year = {2026},
  month = oct,
  doi = {10.1186/s12916-026-05292-y},
  url = {https://link.springer.com/10.1186/s12916-026-05292-y},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Safety, efficacy, and biomarker analysis of HTMC0435 plus temozolomide in relapsed extensive-stage small-cell lung cancer: A phase Ib/II trial
AU  - Sizhe Yu
AU  - Lei Gong
AU  - Jun Qian
AU  - Yanqiu Zhao
AU  - Kaiyan Chen
AU  - Hui Li
AU  - Yanjun Xu
AU  - Guang Han
AU  - Xue Meng
AU  - Jing Qin
AU  - Hongyang Lu
AU  - Na Han
AU  - Cuiping Gu
AU  - Yan Cheng
AU  - Zhiyu Huang
AU  - Yun Fan
PY  - 2026
DA  - 2026/10/08
JO  - BMC Medicine
DO  - 10.1186/s12916-026-05292-y
UR  - https://link.springer.com/10.1186/s12916-026-05292-y
SN  - 1741-7015
ER  -